Literature DB >> 25400187

Long-term complete response in a patient with disseminated pulmonary pleomorphic carcinoma induced by cisplatin and gemcitabine.

Akihiro Tamiya1, Kazuhiro Asami, Shigeki Shimizu, Akihide Matsumura, Shun-Ichi Isa, Kyoichi Okishio, Masanori Kitaichi, Shinji Atagi, Minoru Takada, Tomoya Kawaguchi, Akihito Kubo.   

Abstract

A 47-year-old man was referred to our department due to multiple metastases in the lungs and liver with pleural dissemination six weeks after undergoing curative surgery for lung pleomorphic carcinoma. He received two regimens of chemotherapy, both of which resulted in disease progression. Considering his good general condition, he was treated with cisplatin plus gemcitabine (GP). The metastatic lesions exhibited a complete response after six courses of GP, and the patient has remained free from recurrence for over six years. An immunohistochemical analysis revealed that the tumor was highly expressive of gemcitabine transporter human equilibrative nucleoside transporter 1, thus suggesting a high sensitivity to gemcitabine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25400187     DOI: 10.2169/internalmedicine.53.2637

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma.

Authors:  Yosuke Tamura; Yutaka Fujiwara; Noboru Yamamoto; Hiroshi Nokihara; Hidehito Horinouchi; Shintaro Kanda; Yasushi Goto; Emi Kubo; Shinsuke Kitahara; Kenjiro Tsuruoka; Koji Tsuta; Yuichiro Ohe
Journal:  BMC Res Notes       Date:  2015-12-18

2.  Clinicopathological characteristics, survival outcomes and prognostic factors in pleomorphic carcinoma: a SEER population-based study.

Authors:  Zhongzhong Chen; Jiachang Liu; Lingfeng Min
Journal:  BMC Pulm Med       Date:  2022-03-31       Impact factor: 3.317

3.  Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.

Authors:  Takafumi Yorozuya; Tetsuya Taya; Kento Yasuda; Yutaro Nagano; Makoto Shioya; Hirofumi Chiba; Hiroki Takahashi
Journal:  Thorac Cancer       Date:  2020-02-11       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.